Abstract
COVID-19, the worldwide pandemic which effected the entire health care system, particularly showed its ill effects on patients with many comorbidities. Among the COVID-19 patients admitted in hospital, are with cardiovascular diseases and hypertension where associated with increased risk of mortality. Angiotensin converting enzyme inhibitors (ACEI) and Angiotensin receptor-II blockers (ARB) were used in the management of hypertension and these medications revealed their beneficiary actions in the conditions of COVID -19 with Hypertension. On the other hand, COVID -19 also lead to thromboembolic complications which also required Intensive Care Unit admission within patients representing a unique condition termed as Covid Associated Coagulopathy (CAC). The impact of dual anti-platelet therapy reduced the risk of mechanical ventilation, ICU admission and mortality rate among individuals effected by Covid.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
